Q-omics provides the consensus-scored WDR77 profile across patient tissues and cancer cell-line models. WDR77 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, WDR77 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, WDR77 protein abundance shows 28,588 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where WDR77 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR77 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR77 survival associations across molecular data types. WDR77 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR77 RNA expression–survival associations across cancer types. High WDR77 expression shows unfavorable associations in ACC, LIHC, SKCM and LGG, but favorable associations in UCEC and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for WDR77 RNA expression.
This table summarizes WDR77 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for WDR77. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR77 shows lower tumor expression in KICH and higher tumor expression in COAD, LUAD, LIHC, LUSC and STAD. The COAD box plot shows higher WDR77 RNA expression in tumor versus normal tissue (log2 FC = +1.764, t-test p < 0.001).
This table shows molecular features associated with WDR77 in patient tissues and cancer cell lines. In patient samples, WDR77 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR77 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
